Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target raised by analysts at HC Wainwright from $0.20 to $5.00. They now have a "neutral" rating on the stock.
NeutralReport
Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target raised by analysts at HC Wainwright from $0.20 to $5.00. They now have a "neutral" rating on the stock.
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") [Financial Post (Toronto, Ontario, Canada)]
HighReport
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") [Financial Post (Toronto, Ontario, Canada)]
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: